BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Travis S, Feagan BG, Peyrin-Biroulet L, Panaccione R, Danese S, Lazar A, Robinson AM, Petersson J, Pappalardo BL, Bereswill M, Chen N, Wang S, Skup M, Thakkar RB, Chao J. Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. J Crohns Colitis 2017;11:1317-25. [PMID: 28981846 DOI: 10.1093/ecco-jcc/jjx093] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Narula N, Aruljothy A, Wong ECL, Homenauth R, Alshahrani AA, Marshall JK, Reinisch W. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies. United European Gastroenterol J 2021;9:581-9. [PMID: 34077627 DOI: 10.1002/ueg2.12094] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Wu ZC, Zhao ZL, Deng JP, Huang JT, Wang YF, Wang ZP. Sanhuang Shu'ai decoction alleviates DSS-induced ulcerative colitis via regulation of gut microbiota, inflammatory mediators and cytokines. Biomed Pharmacother 2020;125:109934. [PMID: 32058214 DOI: 10.1016/j.biopha.2020.109934] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
3 Kamat N, Kedia S, Ghoshal UC, Nehra A, Makharia G, Sood A, Midha V, Gupta V, Choudhuri G, Ahuja V. Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study. Indian J Gastroenterol. 2019;38:44-54. [PMID: 30645725 DOI: 10.1007/s12664-018-0922-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
4 Tursi A, Elisei W, Faggiani R, Allegretta L, Valle ND, Forti G, Franceschi M, Ferronato A, Gallina S, Larussa T, Luzza F, Lorenzetti R, Mocci G, Penna A, Rodino' S, Sebkova L, de Medici A, Pranzo G, Ricciardelli C, Grasso G, Scorza S, Zampaletta C, Picchio M. Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers. Medicine (Baltimore) 2018;97:e11897. [PMID: 30142791 DOI: 10.1097/MD.0000000000011897] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
5 Borren NZ, Tan W, Colizzo FP, Luther J, Garber JJ, Khalili H, van Der Woude CJ, Ananthakrishnan AN. Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort Study. Journal of Crohn's and Colitis 2020;14:309-15. [DOI: 10.1093/ecco-jcc/jjz148] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
6 Rasmussen B, Haastrup P, Wehberg S, Kjeldsen J, Waldorff FB. Predictors of health-related quality of life in patients with moderate to severely active ulcerative colitis receiving biological therapy. Scand J Gastroenterol 2020;55:656-63. [PMID: 32442051 DOI: 10.1080/00365521.2020.1768282] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Chandradevan R, Hofmekler T, Mondal K, Harun N, Venkateswaran S, Somineni HK, Ballengee CR, Kim M, Griffiths A, Noe JD, Crandall WV, Snapper S, Rabizadeh S, Rosh JR, Walters TD, Bertha M, Dubinsky MC, Denson LA, Sauer CG, Markowitz JF, Leleiko NS, Hyams JS, Kugathasan S. Evolution of Pediatric Inflammatory Bowel Disease Unclassified (IBD-U): Incorporated With Serological and Gene Expression Profiles. Inflammatory Bowel Diseases 2018;24:2285-90. [DOI: 10.1093/ibd/izy136] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
8 Jain A, Marrie RA, Shafer LA, Graff LA, Patten SB, El-Gabalawy R, Sareen J, Bolton JM, Fisk JD, Bernstein CN. Incidence of Adverse Psychiatric Events During Treatment of Inflammatory Bowel Disease With Biologic Therapies: A Systematic Review. Crohns Colitis 360 2020;2:otz053. [PMID: 32003760 DOI: 10.1093/crocol/otz053] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Wetwittayakhlang P, Lontai L, Gonczi L, Golovics PA, Hahn GD, Bessissow T, Lakatos PL. Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology? J Clin Med 2021;10:5551. [PMID: 34884252 DOI: 10.3390/jcm10235551] [Reference Citation Analysis]
10 Aniwan S, Bruining DH, Park SH, Al-Bawardy B, Kane SV, Coelho Prabhu N, Kisiel JB, Raffals LE, Papadakis KA, Pardi DS, Tremaine WJ, Loftus EV Jr. The Combination of Patient-Reported Clinical Symptoms and an Endoscopic Score Correlates Well with Health-Related Quality of Life in Patients with Ulcerative Colitis. J Clin Med 2019;8:E1171. [PMID: 31387259 DOI: 10.3390/jcm8081171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chiba M, Tsuji T, Nakane K, Tsuda S, Ishii H, Ohno H, Obara Y, Komatsu M, Tozawa H. High Remission Rate with Infliximab and Plant-Based Diet as First-Line (IPF) Therapy for Severe Ulcerative Colitis: Single-Group Trial. Perm J 2020;24:1-10. [PMID: 33482946 DOI: 10.7812/TPP/19.166] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Vitello A, Grova M, Pugliese D, Rizzello F, Lanzarotto F, Lavagna A, Caccaro R, Cappello M, Viola A, Ribaldone DG, Principi M, Stasi E, Scribano ML, Maida M, Soriano A, Bezzio C, Bodini G, Mocciaro F, Privitera AC, Simondi D, Giuffrida E, D'Incà R, Ricci C, Gionchetti P, Armuzzi A, Orlando A, Daperno M; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. Dig Liver Dis 2021:S1590-8658(21)00761-1. [PMID: 34538764 DOI: 10.1016/j.dld.2021.08.020] [Reference Citation Analysis]
13 Viazis N, Pontas C, Manolakis A, Karampekos G, Tsoukali E, Galanopoulos M, Koustenis K, Archavlis E, Christidou A, Gazouli M, Mantzaris GJ. Efficacy of switching from infliximab to golimumab in patients with ulcerative colitis in deep remission. Acta Gastroenterol Belg 2021;84:423-8. [PMID: 34599566 DOI: 10.51821/84.3.007] [Reference Citation Analysis]
14 Yarlas A, Maher SM, Bayliss MS, Lovley A, Cappelleri JC, DiBonaventura MD. Psychometric validation of the work productivity and activity impairment questionnaire in ulcerative colitis: results from a systematic literature review. J Patient Rep Outcomes. 2018;2:62. [PMID: 30547275 DOI: 10.1186/s41687-018-0088-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
15 Thomas PWA, den Broeder N, Derikx M, Kievit W, West RL, Russel MGVM, Jansen JM, Römkens TEH, Hoentjen F. Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective Study. Inflamm Bowel Dis 2022:izac002. [PMID: 35134917 DOI: 10.1093/ibd/izac002] [Reference Citation Analysis]
16 Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. Dig Liver Dis 2021;53:803-8. [PMID: 33744172 DOI: 10.1016/j.dld.2021.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
17 Calviño-Suárez C, Ferreiro-Iglesias R, Bastón-Rey I, Barreiro-de Acosta M. Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment. Int J Environ Res Public Health 2021;18:7159. [PMID: 34281095 DOI: 10.3390/ijerph18137159] [Reference Citation Analysis]
18 Blackwell J, Saxena S, Jayasooriya N, Bottle A, Petersen I, Hotopf M, Alexakis C, Pollok RC. Prevalence and Duration of Gastrointestinal Symptoms Before Diagnosis of Inflammatory Bowel Disease and Predictors of Timely Specialist Review: A Population-Based Study. Journal of Crohn's and Colitis 2021;15:203-11. [DOI: 10.1093/ecco-jcc/jjaa146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
19 Shivaji UN, Bazarova A, Critchlow T, Smith SCL, Nardone OM, Love M, Davis J, Ghosh S, Iacucci M. Clinical outcomes, predictors of prognosis and health economics consequences in IBD patients after discontinuation of the first biological therapy. Therap Adv Gastroenterol 2020;13:1756284820981216. [PMID: 34104206 DOI: 10.1177/1756284820981216] [Reference Citation Analysis]
20 AlRuthia Y, Almadi M, Aljebreen A, Azzam N, Alsharif W, Alrasheed H, Almuaythir G, Saeed M, HajkhderMullaissa B, Alharbi O. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia. J Med Econ 2020;23:1102-10. [PMID: 32619388 DOI: 10.1080/13696998.2020.1791889] [Reference Citation Analysis]
21 Burmester GR, Gordon KB, Rosenbaum JT, Arikan D, Lau WL, Li P, Faccin F, Panaccione R. Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis. Adv Ther 2020;37:364-80. [PMID: 31748904 DOI: 10.1007/s12325-019-01145-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
22 Sakemi R, Miyakawa M, Tanaka H, Nasuno M, Motoya S, Tanuma T, Ishii M, Yanagisawa H, Yamashita M, Toita N, Suzuki R, Kobayashi T, Nojima M, So S. Predicting a rapid response to adalimumab treatment and favorable short-term outcomes through the high platelet count in patients with ulcerative colitis: A multicenter retrospective cohort study. Medicine (Baltimore) 2020;99:e23344. [PMID: 33217875 DOI: 10.1097/MD.0000000000023344] [Reference Citation Analysis]